Afimoxifene

Afimoxifene
  • CAS No.:68392-35-8

Important Notice

  1. This product is a chemical product/pharmaceutical intermediate. It is not a drug, an active pharmaceutical ingredient (API), or a pharmaceutical-grade material. It has not been granted a drug approval number or a Chemical Drug Substance Approval Notice, has not passed drug-related review and approval, and is not manufactured, tested, or released in accordance with pharmaceutical GMP.
  2. This product is intended solely for non-clinical research, process development, quality studies, further chemical processing, or chemical synthesis. It must not be used in drug-product manufacturing, clinical trials, clinical diagnosis, or administration to humans or animals, or be sold, used as an input, submitted for regulatory filing, or released as an API or pharmaceutical material.
  3. The purchaser must not use this product, or supply it to another party, for personal consumption, sports or fitness, weight loss, health supplements, food, or animal feed.
Other grades of this product :
Afimoxifene Basic information
Product Name:Afimoxifene
Synonyms:AFIMOXIFENE;4-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol;4-Hydroxytamoxifen, (E)-isomer;4-Hydroxytamoxifen, (Z)-isomer;4-Monohydroxytamoxifen;4-Oht hydrotamoxifen;C016601;(E/Z)-4-Hydroxy Tamoxifen
CAS:68392-35-8
MF:C26H29NO2
MW:387.51
EINECS:
Product Categories:Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:68392-35-8.mol
Afimoxifene Chemical Properties
Melting point 135-144°C
Boiling point 514.4±50.0 °C(Predicted)
density 1.092
storage temp. 2-8°C
solubility methanol: soluble10mg/mL
form solution
pka9.38±0.15(Predicted)
color white to off-white
Safety Information
Hazard Codes Xn
Risk Statements 63-20/21/22
Safety Statements 22-23-36
RIDADR UN1170 - class 3 - PG 2 - Ethanol, solution
WGK Germany 3
RTECS SL1210000
MSDS Information
Afimoxifene Usage And Synthesis
Chemical PropertiesOff-White Solid
UsesA selective estrogen receptor modulator.
Uses(E/Z)-4-Hydroxy Tamoxifen is selective estrogen receptor modulator.
Brand nameTamoGel (Ascend Therapeutics).
General Description4-Hydroxytamoxifen is a first generation, selective estrogen receptor modulator (SERM) that functions as an antagonist in breast cancer cells but can display estrogen-like activities in the uterus and bone.
Biological Activity4-hydroxytamoxifen is an estrogen receptor modulator.estrogen receptor can be selectively stimulated or inhibited, providing promising therapeutic opportunities for auto-immune diseases, prostate and breast cancer, as well as depression.
Biochem/physiol ActionsMetabolite of the chemotherapeutic drug tamoxifen, exhibiting more potent estrogen agonist/antagonist activity than the parent drug. Also active as intra-membranous inhibitor of lipid peroxidation.
in vitroprevious study was conducted to evaluate the effects of tamoxifen and its active metabolite 4-hydroxytamoxifen on isolated rat cardiac myocyte mechanical function and calcium handling. results showed that myocytes treated with 4-hydroxytamoxifen had similarly to tamoxifen-treated cells to both calcium handling and contractility [1].
in vivoprevious animal study compared the extent of dna adduct formation in sd rats treated with seven tamoxifen or 4-hydroxytamoxifen. results showed that the liver weights and microsomal rates were not changed by tamoxifen or 4-hydroxytamoxifen treatment. moreover, the uterine weights were significantly decreased and uterine peroxidase activity was marginally decreased in tamoxifen or 4-hydroxytamoxifen treated rats. in addition, hepatic dna adduct levels in rats treated with 4-hydroxytamoxifen did not differ from control rats. similaryly, the adduct levels in uterus dna from rats treated with tamoxifen or 4-hydroxytamoxifen were not different from those in control rats [2].
IC 5027 and 18 μm for mcf-7 and mda-mb-231 cell proliferation
references[1] asp ml,martindale jj,metzger jm. direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling. plos one.2013 oct 24;8(10):e78768. [2] beland fa,mcdaniel lp,marques mm. comparison of the dna adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. carcinogenesis.1999 mar;20(3):471-7.[3] lee o et al. a randomized phase ii presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast. clin cancer res.2014 jul 15;20(14):3672-82.

Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Read the full Disclaimer
Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye